Aquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Large Drop in Short Interest

Aquestive Therapeutics, Inc. (NASDAQ:AQST) was the recipient of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 11,090,000 shares, a decline of 5.9% from the January 15th total of 11,790,000 shares. Based on an average daily volume of 1,470,000 shares, the days-to-cover ratio is currently 7.5 days.

Aquestive Therapeutics Trading Down 5.1 %

Shares of NASDAQ:AQST opened at $3.15 on Wednesday. Aquestive Therapeutics has a twelve month low of $2.24 and a twelve month high of $6.23. The company’s 50 day moving average is $3.32 and its 200 day moving average is $4.19. The company has a market cap of $287.22 million, a PE ratio of -7.00 and a beta of 2.67.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on AQST. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research note on Friday, December 20th. Leerink Partners upped their price objective on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Finally, Cantor Fitzgerald assumed coverage on shares of Aquestive Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $11.00.

Hedge Funds Weigh In On Aquestive Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Aquestive Therapeutics by 1.9% in the 4th quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company’s stock worth $15,474,000 after buying an additional 82,958 shares during the period. Geode Capital Management LLC boosted its position in Aquestive Therapeutics by 5.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,667,515 shares of the company’s stock worth $8,306,000 after purchasing an additional 90,543 shares in the last quarter. State Street Corp boosted its position in Aquestive Therapeutics by 52.1% in the 3rd quarter. State Street Corp now owns 1,496,739 shares of the company’s stock worth $7,454,000 after purchasing an additional 512,682 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in Aquestive Therapeutics by 6.6% in the 4th quarter. Janney Montgomery Scott LLC now owns 984,485 shares of the company’s stock worth $3,505,000 after purchasing an additional 61,200 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in Aquestive Therapeutics by 905.2% in the 4th quarter. Bank of America Corp DE now owns 690,284 shares of the company’s stock worth $2,457,000 after purchasing an additional 621,614 shares in the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.